The investment was in the form of a convertible note, according to an April 20 news release. It will support the development of Remedisc, a therapeutic for the treatment of degenerative disc disease.
Pacira plans to make an additional $7 million investment based on future milestones. The investment follows Spine BioPharma’s recent series A financing round.
More articles on biologics:
Florida surgeon performs disc replacement on wrong area of patient’s spine
2 spine surgeon leaders exit Johns Hopkins
5 high-profile device company court battles: Medtronic, Smith+Nephew & more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
